How many clinical trials are tracked for Systemic Inflammatory Response Syndrome?

6 trials are tracked, 0 with published results.

Systemic Inflammatory Response Syndrome Research

Systemic Inflammatory Response Syndrome: current evidence & treatments

Systemic inflammatory response syndrome (SIRS) is a critical condition often associated with sepsis. Diagnostic tools for sepsis-related complications show variable performance: Cystatin C demonstrates good diagnostic accuracy for sepsis-associated acute kidney injury with an AUC of 0.88 ¹, while IL-27 outperforms CRP for neonatal sepsis diagnosis (AUC 0.92) ¹⁶. In low- and middle-income countries, qSOFA has moderate discrimination (AUROC 0.74) with low sensitivity (0.51) but high specificity (0.83), whereas SIRS has higher sensitivity (0.86) but lower specificity (0.32) ¹³. Prediction models for mortality in sepsis show moderate performance (pooled AUC 0.794) ², and models for ARDS occurrence in sepsis have test-phase AUC 0.749 ³.

Management strategies emphasize source control and antibiotic stewardship ⁸, with antibiotic stewardship bundles aiming to reduce antibiotic use in NICUs ⁷. Immunomodulatory therapies show promise: ulinastatin reduces all-cause mortality (RR 0.37) ¹⁷, and interleukin-7 improves lymphocyte counts but not mortality in sepsis ¹¹. Procalcitonin-guided care did not affect early antibiotic initiation but lowered 28-day mortality ²⁵. Long-term outcomes for sepsis survivors are poor, with 44% readmission at 1 year and 42.3% mortality at 5 years, along with persistent cognitive, physical, and psychological impairments ²⁴.

Cystatin C has good diagnostic performance for sepsis-associated acute kidney injury (AUC 0.88) ¹.

IL-27 is superior to CRP for neonatal sepsis diagnosis (AUC 0.92) ¹⁶.

qSOFA has moderate discrimination but low sensitivity in LMICs ¹³.

Ulinastatin shows the most favorable effect on sepsis mortality (RR 0.37) ¹⁷.

Sepsis survivors have high readmission (44% at 1 year) and long-term mortality (42.3% at 5 years) ²⁴.